Literature DB >> 10861449

Expression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cells.

C Ricci1, L Landuzzi, I Rossi, C De Giovanni, G Nicoletti, A Astolfi, S Pupa, S Menard, K Scotlandi, P Nanni, P L Lollini.   

Abstract

Five human rhabdomyosarcoma cell lines were used to investigate the surface expression of HER/erbB receptors, particularly of HER-2, HER-3 and HER-4, by flow cytometry. HER-2 was expressed in 3/5 rhabdomyosarcoma cell lines. HER-3 was expressed in all rhabdomyosarcoma cell lines. None of the rhabdomyosarcoma cell lines investigated showed HER-4 surface expression. To study the biological activity of HER/erbB receptors in rhabdomyosarcomas, cells were cultured in the presence of glial growth factor 2 (GGF-2), a specific ligand of HER-3 that is able to stimulate myogenesis in normal myoblasts. In 3 of 3 human rhabdomyosarcoma cell lines positive for both HER-2 and HER-3 receptors, the treatment with GGF-2 induced a significant increase in myogenic differentiation. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861449

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

Review 1.  Developmental origins of fusion-negative rhabdomyosarcomas.

Authors:  Ken Kikuchi; Brian P Rubin; Charles Keller
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

2.  Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue.

Authors:  Karl-Ludwig Schaefer; Kristin Brachwitz; Yvonne Braun; Raihanatou Diallo; Daniel H Wai; Susanne Zahn; Dominik T Schneider; Cornelius Kuhnen; Arabel Vollmann; Gero Brockhoff; Helmut E Gabbert; Christopher Poremba
Journal:  Neoplasia       Date:  2006-07       Impact factor: 5.715

3.  Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2.

Authors:  Laura Menotti; Arianna Cerretani; Hartmut Hengel; Gabriella Campadelli-Fiume
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

4.  Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.

Authors:  Judith Niesen; Christoph Stein; Hannes Brehm; Grit Hehmann-Titt; Rolf Fendel; Georg Melmer; Rainer Fischer; Stefan Barth
Journal:  J Cancer Res Clin Oncol       Date:  2015-04-22       Impact factor: 4.322

5.  Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma.

Authors:  Lisa E S Crose; Corinne M Linardic
Journal:  Sarcoma       Date:  2011-01-02

6.  Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274.

Authors:  Jinxuan Hou; Jixin Dong; Lijun Sun; Liying Geng; Jing Wang; Jialin Zheng; Yan Li; Julia Bridge; Steven H Hinrichs; Shi-Jian Ding
Journal:  J Transl Med       Date:  2011-05-16       Impact factor: 5.531

7.  Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.

Authors:  P Nanni; G Nicoletti; C De Giovanni; L Landuzzi; E Di Carlo; F Cavallo; S M Pupa; I Rossi; M P Colombo; C Ricci; A Astolfi; P Musiani; G Forni; P L Lollini
Journal:  J Exp Med       Date:  2001-11-05       Impact factor: 14.307

Review 8.  Rhabdomyosarcomas: an overview on the experimental animal models.

Authors:  Alessandra Zanola; Stefania Rossi; Fiorella Faggi; Eugenio Monti; Alessandro Fanzani
Journal:  J Cell Mol Med       Date:  2012-07       Impact factor: 5.310

9.  Comparison of a mouse and a novel human scFv-SNAP-auristatin F drug conjugate with potent activity against EGFR-overexpressing human solid tumor cells.

Authors:  Mira Woitok; Diana Klose; Stefano Di Fiore; Wolfgang Richter; Christoph Stein; Gerrit Gresch; Elena Grieger; Stefan Barth; Rainer Fischer; Katharina Kolberg; Judith Niesen
Journal:  Onco Targets Ther       Date:  2017-07-06       Impact factor: 4.147

10.  Analysis of copy number loss of the ErbB4 receptor tyrosine kinase in glioblastoma.

Authors:  DeAnalisa C Jones; Adriana Scanteianu; Matthew DiStefano; Mehdi Bouhaddou; Marc R Birtwistle
Journal:  PLoS One       Date:  2018-01-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.